It is assumed that the candidate for the vaccine COVID-19 from BioNTech SE and Pfizer Inc will be ready to receive regulatory approval by the end of 2020, according to the Wall Street Journal, citing the chief executive officer of the German biotechnology company.
It is estimated that the BioNTech SE and Pfizer Inc vaccine candidate COVID-19 will be ready to receive regulatory approval by the end of 2020, the Wall Street Journal reported with reference to the chief executive officer of the German biotechnology company.
The pilot vaccine, which has shown a promising role in combating rapidly spreading respiratory diseases in the early stages of human testing, is expected to enter a large trial with 30,000 healthy participants pending regulatory approval at the end of this month.
If the company receives marketing approval, by the end of 2020 it will prepare up to 100 million doses, and by the end of 2021, another 1.2 billion doses at facilities in Germany and the USA, Reuters reported last week.
According to a WSJ report, several hundred million doses may be delivered prior to approval.
BioNTech’s CEO warns that fighting a virus that has now infected millions of people could take a decade, despite global efforts and rapid progress.